Prognostic factors in Hodgkin's lymphoma

被引:26
作者
Zander, T [1 ]
Wiedenmann, S [1 ]
Wolf, J [1 ]
机构
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
关键词
Hodgkin's lymphoma; prognostic factors; risk; treatment strategies;
D O I
10.1093/annonc/13.S1.67
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Risk-adapted treatment strategies have constituted a major issue since the beginning of clinical research into Hodgkin's disease (HD). Various prognostic factors have been identified and several of those considered for staging procedures, resulting in strictly stage-dependent treatment recommendations for patients suffering from HD. These factors may be subdivided in host-related (e.g. age, sex) and tumour-related (e.g. number of tumour cells, growth characteristics, spread of tumour cells, resistance to apoptosis) factors. Owing to the striking improvement of the overall prognosis in HD patients it may be difficult to identify novel prognostic factors analysing the minority of patients with a fatal outcome. However, especially in advanced-stage disease, improved treatment results were achieved by the introduction of more aggressive treatment regimens, resulting in an increased toxicity rate. Thus, partially in contrast to earlier work in this field, future prognostic factors are needed for identification of those patients that have a good prognosis and might be susceptible to overtreatment. During the Fifth International Symposium on Hodgkin's Lymphoma, promising results on several new prognostic markers were presented. Furthermore, a joint effort to design new studies on large, well characterised patient groups has been initiated.
引用
收藏
页码:67 / 74
页数:8
相关论文
共 153 条
  • [1] Abele MC, 1997, HAEMATOLOGICA, V82, P281
  • [2] AMBROSETTI A, 1993, CANCER, V72, P201, DOI 10.1002/1097-0142(19930701)72:1<201::AID-CNCR2820720136>3.0.CO
  • [3] 2-V
  • [4] A RANDOMIZED STUDY OF ADJUVANT CHEMOTHERAPY AFTER MANTLE RADIOTHERAPY IN SUPRADIAPHRAGMATIC HODGKINS-DISEASE PS-IA-IIB - A REPORT FROM THE MANCHESTER LYMPHOMA GROUP
    ANDERSON, H
    DEAKIN, DP
    WAGSTAFF, J
    JONES, JM
    TODD, IDH
    WILKINSON, PM
    JAMES, RD
    STEWARD, WP
    BLACKLEDGE, G
    SCARFFE, JH
    CROWTHER, D
    [J]. BRITISH JOURNAL OF CANCER, 1984, 49 (06) : 695 - 702
  • [5] [Anonymous], LEUKEMIA LYMPHOMA S2
  • [6] AULBERT E, 1990, ONKOLOGIE, V13, P102
  • [7] Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease
    Axdorph, U
    Sjöberg, J
    Grimfors, G
    Landgren, O
    Porwit-MacDonald, A
    Björkholm, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (11) : 1405 - 1411
  • [8] SYSTEMIC TREATMENT OF CANCER IN THE ELDERLY
    BALDUCCI, L
    PHILLIPS, DM
    DAVIS, KM
    FILES, JC
    KHANSUR, T
    HARDY, CL
    [J]. ARCHIVES OF GERONTOLOGY AND GERIATRICS, 1988, 7 (02) : 119 - 150
  • [9] ASSESSMENT OF BONE-MARROW HISTOLOGY IN HODGKINS-DISEASE - CORRELATION WITH CLINICAL FACTORS
    BARTL, R
    FRISCH, B
    BURKHARDT, R
    HUHN, D
    PAPPENBERGER, R
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (03) : 345 - 360
  • [10] BECKER JC, 1993, J IMMUNOL, V151, P7224